The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery  by Rothenburger, Markus et al.
Bypass Surgery
The Impact of Anti-Endotoxin Core
Antibodies on Endotoxin and Cytokine
Release and Ventilation Time After Cardiac Surgery
Markus Rothenburger, MD,* Rasjid Soeparwata, MD,* Mario C. Deng, MD, FACC, FESC,†
Elmar Berendes, MD,‡ Christof Schmid, MD,* Tonny D. T. Tjan,* Markus J. Wilhelm, MD,*
Michael Erren, MD,§ Dirk Bo¨cker, MD,\ Hans Heinrich Scheld, MD*
Muenster, Germany and New York, New York
OBJECTIVES We hypothesized that a temporary cardiopulmonary bypass (CPB)-induced reduction of
endotoxin antibody levels contributes to elevated endotoxin levels and the associated
inflammatory consequences, with a significant influence on the postoperative ventilation time
period.
BACKGROUND Cardiac surgery using CPB induces a systemic inflammatory response syndrome with an
associated risk of increased postoperative morbidity and mortality.
METHODS A total of 100 consecutive patients undergoing elective coronary artery bypass graft surgery
using CPB were prospectively investigated. Endotoxin core antibodies (immunoglobulin [Ig]
M/IgG against lipid A and lipopolysaccharide), endotoxin, interleukin (IL)-1-beta, IL-6,
IL-8 and tumor necrosis factor-alpha were measured serially from 24 h preoperatively until
72 h postoperatively.
RESULTS Eighty-five patients had no complications (group 1), whereas 15 patients required prolonged
ventilation (group 2). In both groups, there was a decrease of all antibodies 5 min after CPB
onset, compared with baseline values (p , 0.001), an increase of endotoxin and IL-8 peaking
at 30 min postoperatively (p , 0.001) and an increase of IL-6 peaking 3 h postoperatively
(p , 0.001). In group 2, preoperative antibody levels were lower (p , 0.01)—specifically, the
decrease in IgM was significantly stronger and of longer duration (p , 0.002)—and levels of
endotoxin (p , 0.001) and IL-8 (p , 0.001) were higher at 30 min postoperatively.
CONCLUSIONS We conclude that an CPB-associated temporary reduction of anti-endotoxin core antibody
levels contributes to elevated endotoxin and IL-8 release. Furthermore, lower levels of IgM
anti-endotoxin core antibodies were associated with a greater rise in endotoxin and IL-8, as
well as prolonged respirator dependence. (J Am Coll Cardiol 2001;38:124–30) © 2001 by
the American College of Cardiology
Cardiac surgery using cardiopulmonary bypass (CPB) fre-
quently results in a systemic inflammatory response syn-
drome, including fever, and leukocytosis (1,2). The inflam-
matory response syndrome can lead to hemodynamic
instability, respiratory insufficiency and multiorgan failure
(1,2). The consequences of uncontrolled activation of the
proinflammatory response is evident microscopically in dif-
ferent organs as diffuse microvascular thrombi lead to organ
failure, especially of the lung (3). This may be induced by
proinflammatory cascades with coagulopathy after an im-
balance of hemostatic mechanisms and chemokine-induced
alterations of leukocyte homing. Although the initiation of
this sequence is coincident with CPB, the mechanisms
remain to be elucidated.
Endotoxin is recognized to be a major stimulus for the
development of the systemic inflammatory response syn-
drome (4). The lipopolysaccharide (LPS) component of the
cell wall of gram-negative bacteria is believed to be respon-
sible for the majority of the pathogenic effects of these
organisms. Endotoxin causes an increase in tissue oxygen
demand, myocardial dysfunction and complement activa-
tion and triggers contact activation, which may lead to a
bleeding tendency and microvascular thrombosis, a major
cause of organ failure (5). Exposure to endotoxin is known
to occur in most patients undergoing surgery involving CPB
(6), although the origin of the endotoxin remains a subject
of great debate. Translocation secondary to gut hypoperfu-
sion has long been considered as one possible source (7),
and, with large fluid shifts and low perfusion pressures
encountered during bypass surgery, it remains an attractive
hypothesis.
Starting in early fetal life, humans possess a degree of
endogenous endotoxin immunity conferred initially by ma-
ternal transfer and subsequently enhanced by exposure to
endotoxin (8,9). Anti-endotoxin core antibodies of the
different antibody classes are commonly present in substan-
tial amounts in the sera of most healthy adults (8,9).
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The only area of the endotoxin molecule that is conserved
across a whole range of gram-negative organisms is the
inner core region. Therefore, it can be assumed that anti-
bodies in this area should be most cross-reactive and thus
most protective (10).
Bennett-Guerrero et al. (11) described the association
between preoperative anti-endotoxin immune status and
morbidity in patients who had cardiac surgery. The authors
demonstrated that low preoperative serum immunoglobulin
(Ig) M anti-endotoxin core antibody concentrations were
associated with adverse outcome after cardiac surgery, com-
pliant with the concept that endotoxemia may be an
important cause of perioperative morbidity after cardiac
surgery.
These data imply that anti-endotoxin core antibodies are
important in preventing an endotoxin-induced overshoot of
the immunologic host response, with cytokine release and
adverse events (12). However, changes in antibody levels
during CPB have not been examined.
The hypothesis tested in this study is that low preoper-
ative endogenous anti-endotoxin core antibody levels in
patients undergoing coronary artery bypass graft surgery
(CABG) result in higher postoperative endotoxin and
cytokine levels. A secondary objective was to relate these
changes to the duration of respirator dependence.
METHODS
Patients. Study participants included patients undergoing
elective CABG in our institution. Study inclusion criteria
were: 1) age between 18 and 75 years; 2) preoperative left
ventricular ejection fraction .0.45; 3) stable clinical condi-
tion; and 4) consent declaration to participate in the study,
which was approved by the Ethics Committee (University
of Muenster, Germany). Patients were characterized using
the risk score reported by Estefanous et al. (13).
Clinical events. Group 1 was defined as those patients
requiring a ventilation time ,24 h (group 1A 5 ventilation
time ,12 h; group 1B 5 ventilation time 12 to 24 h).
Patients requiring a ventilation time .24 h postoperatively
were defined as the event group (group 2).
Weaning from the respirator was attempted some hours
after arrival in intensive care unit if patients were hemody-
namically stable. In patients with stable blood gases and low
chest tube secretion, rapid extubation was accomplished by
reducing the rate in a synchronized intermittent mandatory
ventilation mode. All outcome measurements (extubation
time) were performed by clinicians who had no knowledge
of the patients’ antibody, endotoxin and cytokine levels.
Blood sampling. Blood was drawn at 11 time points. The
blood sampling was done 24 h before surgery (time point
[TP] 1), after induction of anesthesia (TP 2), after sternot-
omy (TP 3), 5 min after CPB onset (TP 4), after protamine
reversal (TP 5), during skin closure (TP 6) and 30 min (TP
7), 3 h (TP 8), 24 h (TP 9), 48 h (TP 10) and 72 h
postoperatively (TP 11).
The first and postoperative blood samples were collected
by venipuncture (21-gauge butterfly needle); all other sam-
ples were taken using the arterial line.
Blood was collected into Vacutainer tubes containing
buffered ethylenediaminetetraacetic acid (EDTA)-K3
(15%, 0.084 ml, 0.34 mol/l; Becton Dickinson) and into
EndoTubes containing sodium heparin (120 IU, endotoxin-
free, 4 ml; Chromogenix, Sweden) that were immediately
placed on ice and processed within 30 min.
The EDTA plasma for interleukin (IL)-1-beta, IL-6 and
tumor necrosis factor (TNF)-alpha determination was ob-
tained by centrifugation at 4,000 3 g, 4°C for 20 min.
Sodium heparin-anticoagulated plasma for determination of
endotoxin and anti-endotoxin core antibodies was obtained
by centrifugation at 1,000 3 g at room temperature for
10 min. Sodium heparin-anticoagulated plasma for deter-
mination of IL-8 was obtained by centrifugation at 4,000 3
g at 4°C for 20 min. Aliquots of plasma were snap-frozen in
liquid nitrogen and stored at 280°C until analyzed.
Blood cultures were obtained, on average, on the third
postoperative day in patients with clinical evidence of
infection (i.e., fever .39°C and radiologic or clinical signs
of infection). In patients without clinical evidence of infec-
tion, no blood cultures were obtained.
All laboratory measurements were performed on coded
samples so the investigators would have no knowledge of
the patients’ identity and outcome.
Analysis of cytokines. Levels of IL-1-beta, TNF-alpha,
IL-6 and IL-8 in the plasma were determined by means of
a commercially available enzyme-linked immunosorbent
assay (ELISA; R&D systems, Biermann, Bad Nauheim,
Germany).
Analysis of endotoxins. A commercially available chromo-
genic Limulus amebocyte lysate test for endotoxin measure-
ment (Coatest Endotoxin, Kabi-Chromogenix, Mo¨lndal,
Sweden) was carried out.
All reagents (Kabi Vitrium, Stockholm, Sweden) and
materials were endotoxin-free, and all preparation steps,
except for photometry, were performed under sterile condi-
tions. To minimize contamination, blood samples from
healthy donors served as negative control samples.
Analysis of anti-endotoxin core antibodies. Semiquanti-
tative ELISA for determination of IgM and IgG antibodies
against lipid A and LPS were performed as previously
described (14). The lower detection limits were 3.9 U/ml for
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IgM against lipid A, 4.3 U/ml for IgM against LPS, 8 U/ml
for IgG against lipid A and 8.1 U/ml for IgG against LPS.
During the first step, microtiter plates were coated with
lipid A and LPS, separately, for 24 h (coating buffer:
Na2CO3, NaHCO3, NaN3 in ad water; pH 9.6). The
plasma of the patient samples was added and incubated for
1.5 h at room temperature. Thereafter, the plasma samples
were washed out three times using phosphate-buffered
saline (PBS) Tween wash solution (NaCl, Na2HPO4 3
[H2O]2, KCl, KH2PO4, NaN3, Tween 20 in ad water; pH
7.4). In the next step, mouse antibodies against human IgM
and IgG, separately (conjugated buffer: PBS Tween 1 4%
polyethylene glycol molecular weight 6,000) were added.
After incubation for 16 h, a chromogenic substrate (p-
nitrophenyl phosphate, 1 mg/ml) in substrate buffer (dieth-
anolamin, MgCl2 3 6 H2O, NaN3; pH 9.8) was added.
The samples were photometrically measured at 405 nm.
The results are displayed as units/microliter, which is related
to the photometric index derived from the assay methodol-
ogy.
Hemodilution. The measured serum concentration of a
biologically active compound is relevant for the response of
the patient. However, to compare the intraoperative results
with the preoperative and postoperative levels, it was nec-
essary to correct the concentrations measured during bypass
for hemodilution. Volume correction was performed by the
formula:
Ccorr 5 Cmeas 3 Htanesth/Htcpb
where Ccorr is the corrected concentration; Cmeas is the
measured concentration; Htanesth is the hematocrit value
after anesthesia; and Htcpb is the hematocrit value during
CPB (corr 5 correction; meas 5 measurement; anesth 5
induction of anesthesia; cpb 5 during/after CPB). Correc-
tion for hemodilution was performed for samples taken
during and after CPB. Only corrected data are depicted and
used for statistical analysis.
Statistical analysis. For statistical analysis, the Statistical
Package for the Social Sciences (SPSS version 9.01, Chi-
cago, Illinois) was used. After log transformation, a normal
distribution of the variables was confirmed. A descriptive
statistical analysis of cytokine, endotoxin and antibody levels
was performed and presented as the mean value 6 SD.
Analysis of variance for repeated measures was performed
according the Scheffe´ post hoc comparison. Preoperative
antibody levels were used as covariates (independent vari-
ables) in the statistical analysis. The dependent variables
(antibodies, endotoxins and cytokines) were included in the
model as the change from baseline (preoperative values). A
type I error ,5% was considered significant.
RESULTS
Clinical outcomes. One-hundred patients undergoing
elective CABG were included. The patient characteristics
and perioperative data are presented in Tables 1 and 2. All
consecutive patients received at least one internal mammary
artery graft on the left anterior descending coronary artery.
All patients survived the hospital stay, and no patient
required re-exploration for bleeding after the operation.
Eighty-five of 100 patients were extubated within 24 h
(group 1A: n 5 51; group 1B: n 5 34). Fifteen patients
required ventilation .24 h postoperatively (group 2) (Table
2). In group 2, blood cultures for bacterial agents were
positive in 66% of cases. Blood culture sampling was done,
on average, 48 6 9 h postoperatively (Staphylococcus aureus
[n 5 2], coagulase-negative staphylococcus [n 5 5] and
Table 1. Patient Characteristics and Clinical Data
Group 1
(n 5 85)
Group 2
(n 5 15)
p
Value
Gender (male/female) 63/22 11/4
Age (years) 62.5 (53.4–66.9) 64.3 (51.6–71.2) NS
Body surface (m2) 1.89 (1.78–1.95) 1.83 (1.71–1.92) NS
Risk score* 0.5 (0–2) 1 (0.5–1.5) NS
Preoperative ejection fraction (%) 63 (43–69) 61 (45–70) NS
Extent of vessel involvement (n) 2.5 (1.8–3) 2.5 (1.8–3) NS
*See reference 13. Data are presented as the number of patients or median (interquartile range).
NS 5 not significant.
Table 2. Operative and Postoperative Data
Group 1A Group 1B
p Value
(Group 1A vs. 1B) Group 2
p Value
(Group 1 vs. 2)
No. of CABGs 3.1 6 1 3.1 6 1 NS 3.3 6 1 NS
CPB time (min) 70 6 12 70 6 13 NS 73 6 14 0.05
Cross-clamp time (min) 41 6 7 41 6 7 NS 43 6 8 NS
Operation time (min) 132 6 16 132 6 18 NS 139 6 21 0.05
Ventilation time (h) 9.8 6 4.3 16 6 5.6 0.048 34.8 6 9.2 ,0.001
Postoperative hospital time (days) 6.2 6 2 6.5 6 3 NS 14.5 6 5 ,0.001
Data are presented as the mean value 6 SD.
CABGs 5 coronary artery bypass graft surgeries; CPB 5 cardiopulmonary bypass; NS 5 not significant.
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Pseudomonas aeruginosa [n 5 3]). In group 1, no patient had
clinical symptoms requiring blood cultures.
Anti-endotoxin core antibody levels. In the total group, a
significant decrease of all anti-endotoxin core antibodies
occurred at CPB onset (p , 0.001; Fig. 1). In subgroups 1A
and 1B, antibodies of the IgM type were significantly
decreased compared with baseline values at post-CPB TPs
4 to 8 (p , 0.01). Group 2, patients had significantly lower
preoperative antibody levels (p , 0.001) and a more
pronounced decrease of anti-endotoxin core antibodies at
72 h postoperatively compared with baseline values (IgM
lipid A: p , 0.02; IgM Re[recombinant]LPS: p , 0.05;
IgG lipid A: p , 0.05; IgG ReLPS: p , 0.02). In group 2,
antibodies of the IgM type were significantly decreased
compared with baseline values at all post-CPB TPs (p ,
0.01; Fig. 1).
Endotoxin levels. Preoperatively, no endotoxins were de-
tectable. Thirty minutes after termination of CPB, an
increase of endotoxin, compared with baseline values, oc-
curred (p , 0.001; Fig. 2). A significant influence of the
endotoxin peak levels at 30 min after CPB on postoperative
ventilation time was found (p , 0.001; Table 3). In group
2, patients had a significantly greater rise of endotoxin levels
at TPs 5 to 11 (p , 0.001).
Cytokine levels. Preoperative levels of IL-8 were similar in
all groups. We found a significant elevation of IL-8 in all
groups 30 min after CPB (group 1A: p , 0.002; group 1B:
p , 0.01; group 2: p , 0.001; Fig. 3). The IL-8 ranges at
30 min after CPB were significantly associated with post-
operative ventilation time (p , 0.001; Table 3). A greater
rise of IL-8 levels was significantly associated with lower
preoperative antibodies in group 2 patients (p , 0.01).
Interleukin-8 increased 2 h before the IL-6 peak occurred
(p , 0.001).
The preoperative IL-6 levels were low and not different
between the two groups. Interleukin-6 increased postoper-
Figure 1. Time course of anti-endotoxin core antibodies perioperatively in patients undergoing coronary artery bypass graft surgery without adverse events
(groups 1A and 1B) compared with that in patients with prolonged mechanical ventilation time (group 2) (mean value 6 SD). Time points: 1) preoperative;
2) induction of anesthesia; 3) sternotomy; 4) cardiopulmonary bypass onset; 5) protamine reversal; 6) skin closure; 7) 30 min postoperatively; 8) 3 h
postoperatively; 9) 24 h postoperatively; 10) 48 h postoperatively; and 11) 72 h postoperatively. *p , 0.01. Ig 5 immunoglobulin; LPS 5 lipopolysaccharide.
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atively compared with baseline values in all groups, reaching
its maximum at 3 h after CPB (p , 0.001). No significant
difference between group 1 and 2 patients was observed. In
all groups, a significant increase of TNF-alpha at the end of
the operation, compared with baseline values, was deter-
mined (p 5 0.05). Tumor necrosis factor-alpha did not
differ between the groups. No significant change of IL-1-
beta levels was observed.
Ventilation time and blood culture results. When com-
paring endotoxin and IL-8 levels of group 2 patients with
positive blood cultures (n 5 10) with those of patients with
negative blood cultures (n 5 5), no significant differences
were found.
DISCUSSION
Patients undergoing CABG using CPB demonstrate a
temporary decrease of endotoxin antibody levels, followed
by an increase of endotoxin and IL-8. Patients requiring
prolonged respirator therapy demonstrate lower preopera-
tive IgM antibody levels, a more pronounced reduction in
antibody levels intraoperatively and postoperatively and a
significantly greater release of endotoxin and IL-8.
Anti-endotoxin core antibodies and CPB. Anti-
endotoxin core antibodies show an initial depletion in
sepsis, as well as acute pancreatitis, predicting the develop-
ment of multiorgan failure (15). However, results in cardiac
surgery using CPB are conflicting. Andersen et al. (6) could
not find any changes in the plasma levels of anti-endotoxin
core antibodies after CPB. Bennett-Guerrero et al. (11)
found low preoperative IgM endotoxin antibody levels to be
associated with adverse outcome after cardiac surgery, inde-
pendent of other established risk factors. Hamilton-Davies
et al. (3) reported a relationship between preoperative
endotoxin immune status, gut perfusion and outcome after
valve replacement surgery. They found an increased risk of
postoperative complications in cases of low preoperative
IgG and IgM endotoxin core antibody levels. The investi-
gators concluded that low preoperative endotoxin core
antibody levels are related to a poor outcome after cardiac
surgery.
In support of these results, we found lower preoperative
Figure 2. Time course of endotoxin levels perioperatively in patients undergoing coronary artery bypass graft surgery requiring ventilation time ,12 h
(group 1A); 12 to 24 h (group 1B) and .24 h (prolonged ventilation; group 2) (mean value 6 SD). Time points are described in Figure 1. *p , 0.001.
Table 3. Endotoxin and Interleukin-B Ranges at 30 Minutes
After Cardiopulmonary Bypass and Associated Ventilation Time
n
Ventilation Time
(h)
p
Value
Endotoxin (pg/ml)
,10 56 11.4 6 14.8 ,0.02
11–20 22 14.3 6 16.4 ,0.02
.20 22 34 6 19.5 ,0.001
Interleukin-8 (pg/ml)
,100 8 9.2 6 6.9 ,0.02
101–200 55 18.3 6 14.4 ,0.02
.200 37 23.5 6 19.6 ,0.001
Data are presented as the number of patients and mean value 6 SD.
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levels of anti-endotoxin core antibodies, specifically of the
IgM type, in patients with prolonged respirator therapy.
However, all preoperative antibody levels were within the
normal range. Furthermore, we found a more pronounced
depletion of all IgM antibodies at CPB onset in the event
group. In this group, all antibodies remained decreased
throughout the observation period. These results suggest
that an antibody deficiency with a temporary reduction in
immune competence is accompanied by prolonged respira-
tor dependence after cardiac surgery. The mechanisms of
intraoperative antibody depletion may include adherence to
CPB coating, consumption and decreased production.
Endotoxin and CPB. In current concepts, high levels of
circulating endotoxins during CPB have been assumed to be
caused by splanchnic congestion and translocation of bac-
teria from the intestinal mucosa into the circulation (16,17).
The early depletion of all anti-endotoxin core antibodies
during CPB may cause an imbalance between antigen
(endotoxin) and antibodies, resulting in increased levels of
endotoxin, with consecutive activation of B cells, T cells and
leukocytes. This may provide an alternative explanation for
endotoxin elevation. It has been reported that high endo-
toxin levels are recognized to be a major stimulus of the
systemic inflammatory response syndrome and, subse-
quently, multiorgan failure (3). We found increased endo-
toxin levels peaking 30 min after CPB. A strong association
between endotoxin peak levels at 30 min after CPB and
postoperative ventilation time was determined.
Proinflammatory cytokines and CPB. The higher eleva-
tion of IL-8 in the event group may provide a link between
endotoxin and clinical events. Various studies demonstrated
increased IL-8 levels in patients undergoing CPB (12,18–
20). Because IL-8 is known as a selective chemoattractant
for neutrophils, which play an important role in reperfusion
injury, an increasing number of studies have focused on this
cytokine. Interleukin-8 is involved in cell injury after neu-
trophil activation, pathogenesis of adult respiratory distress
syndrome, multiorgan failure and left ventricular wall mo-
tion abnormalities (12,21,22).
Our results suggest that release of IL-8 follows a dysba-
lance of the endotoxin/endotoxin antibody ratio. Elevation
of IL-8 is associated with consecutive neutrophil activation
after CPB and may play an important role in the pathogen-
esis of the prolonged respirator dependence after cardiac
surgery.
Release of IL-6 after cardiopulmonary bypass was re-
ported in numerous studies (1,19,23). Consistent with
previously reported data, in the present study, a significant
increase 3 h after CPB termination in both groups was
observed. However, in our study, IL-6 had no discrimina-
tory power regarding the ventilation time after cardiac
surgery.
Conclusions. Our data suggest a key role for a CPB-
induced temporary reduction of anti-endotoxin core anti-
bodies and a consecutive increase of endotoxin and IL-8,
associated with prolonged respirator dependence. Low pre-
Figure 3. Time course of interleukin-8 perioperatively in patients undergoing coronary artery bypass graft surgery requiring ventilation time ,12 h (group
1A), 12 to 24 h (group 1B) and .24 h (prolonged ventilation; group 2) (mean value 6 SD). Time points are described in Figure 1. *p , 0.001.
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operative anti-endotoxin core antibody levels are associated
with prolonged respirator dependence after cardiac surgery,
independent of other established risk factors. The data
provide a rationale for the study of immunoglobulin substi-
tution, which may help reduce ventilator time, hospital stay
and cost of treatment.
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